In a small study of twenty-two Texan youths who aged out of the system, 23 percent had a history of suicide attempts.A Swedish study utilizing the data of almost one million people including 22,305 former foster children who had been in care prior to their teens, concluded:

Former child welfare clients were in year of birth and sex standardised risk ratios (RRs) four to five times more likely than peers in the general population to have been hospitalised for suicide attempts....Individuals who had been in long-term foster care tended to have the most dismal outcome...former child welfare/protection clients should be considered a high-risk group for suicide attempts and severe psychiatric morbidity. Death rate
Children in foster care have an overall higher mortality rate than children in the general population. A study conducted in Finland among current and former foster children up to age 24 found a higher mortality rate due to substance abuse, accidents, suicide and illness. The deaths due to illness were attributed to an increased incidence of acute and
chronic medical conditions and developmental delays among children in foster care. Georgia Senator Nancy Schaefer published a report "The Corrupt Business of Child Protective Services" stating: "The National Center on Child Abuse and Neglect in 1998 reported that six times as many children died in foster care than in the general public and that once removed to official "safety", these children are far more likely to suffer abuse, including sexual molestation than in the general population".
Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.Dacomitinib has advanced to several Phase III clinical trials. The January 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing.In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.Dacomitinib was approved for medical use in the United States in September 2018, in Japan in 2019, and in the European Union in 2019, for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation. References
External links
"Dacomitinib". Drug Information Portal. U.S. National Library of Medicine.